*Average 12-month price target from 1 stock analysts.
No financial data available for this stock yet.
Ritter Pharmaceuticals, Inc.
Andrew J. Ritter
June 24, 2015
Ritter Pharmaceuticals develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. Its lead product candidate is RP-G28, an orally administered galacto-oligosaccharide that is in Phase III clinical trials for the treatment of lactose intolerance. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.